SCHEMBL1315091

SCHEMBL1315091

CC1(C)c2cccc(P(C(C)(C)C)C(C)(C)C)c2Oc2c(P(C(C)(C)C)C(C)(C)C)cccc21

nearest known ligand 0.58

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
DRD1 P21728 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29589463 1.00 DRD1 (0.58) DRD1
SCHEMBL29883736 1.00 DRD1 (0.58) DRD1
SCHEMBL15883111 0.92 DRD1 (0.51) DRD1
SCHEMBL10048474 0.85 DRD1 (0.45) DRD1
SCHEMBL709261 0.79 DRD1 (0.64) DRD1
SCHEMBL29867522 0.79 DRD1 (0.64) DRD1
SCHEMBL16987374 0.79 DRD1 (0.51) DRD1
SCHEMBL15871415 0.78 DRD1 (0.62) DRD1
SCHEMBL21374252 0.78 DRD1 (0.62) DRD1
SCHEMBL30066813 0.78 DRD1 (0.62) DRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 315 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388564-A1 METHODS OF MANUFACTURING PYRIDAZINONE COMPOUNDS EDGEWISE THERAPEUTICS INC (US) 2025-12-25 US claimed
EP-4522599-A1 METHODS OF MANUFACTURING PYRIDAZINONE COMPOUNDS EDGEWISE THERAPEUTICS, INC. (US) 2025-03-19 EP claimed
EP-3694864-B1 BORONIC ACID DERIVATIVES AND SYNTHESIS THEREOF QPEX BIOPHARMA INC (US) 2025-03-05 EP claimed
CN-119317621-A Process for preparing pyridazinone compounds 艾知怀斯治疗学公司 2025-01-14 CN claimed
US-20240279399-A1 POLYMERS FOR USE IN ELECTRONIC DEVICES U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS NOTES COLLATERAL AGENT 2024-08-22 US claimed
WO-2023220180-A1 METHODS OF MANUFACTURING PYRIDAZINONE COMPOUNDS EDGEWISE THERAPEUTICS, INC. (US) 2023-11-16 WO claimed
CN-116368134-A Methods of making ubiquitin JAK inhibitors and related intermediate compounds 施万生物制药研发IP有限责任公司 2023-06-30 CN claimed
CN-115612310-A Porphyrin photosensitive dye and application thereof 杭州中美华东制药有限公司 2023-01-17 CN claimed
US-11286270-B2 Boronic acid derivatives and synthesis thereof QPEX BIOPHARMA, INC. (US) 2022-03-29 US claimed
US-20200407373-A1 BORONIC ACID DERIVATIVES AND SYNTHESIS THEREOF QPEX BIOPHARMA, INC. 2020-12-31 US claimed
WO-2019075084-A1 BORONIC ACID DERIVATIVES AND SYNTHESIS THEREOF QPEX BIOPHARMA, INC. (US) 2019-04-18 WO claimed
US-10053426-B2 Process for the synthesis of metyrapone and alkylated metyrapone analogs ALBEMARLE CORPORATION (US) 2018-08-21 US claimed
EP-3237383-A1 ONE-STEP PROCESS FOR THE SYNTHESIS OF ALKYLATED METYRAPONE ANALOGS Albemarle Corporation (US) 2017-11-01 EP claimed
WO-2016105619-A1 ONE-STEP PROCESS FOR THE SYNTHESIS OF ALKYLATED METYRAPONE ANALOGS ALBEMARLE CORPORATION (US) 2016-06-30 WO claimed
CN-105601495-A Synthesis method of netupitant intermediates HEFEI LEAF BIO-TECH CO LTD 2016-05-25 CN claimed
CN-105541594-A Synthetic method for netupitant intermediate 2-(3,5-bistrifluoromethylphenyl)-2-methyl propionate HEFEI LIFU BIOTECHNOLOGY CO LTD 2016-05-04 CN claimed
CN-105541593-A Method for synthesizing drug intermediate HEFEI LIFU BIOTECHNOLOGY CO LTD 2016-05-04 CN claimed
CN-105523916-A Method for synthetizing Netupitant midbody impurity 2-(3,5-Bis-trifluoromethyl-phenyl) propionic acid INST OF ADVANCED TECH UNIV OF SCIENCE AND TECH OF CHINA 2016-04-27 CN claimed
CN-104447679-B The preparation method of a kind of 2 thiophene acetonitrile and 2 thiophene ethyl amine Advanced technology research institute of China Science & Technology University (CN) 2016-04-13 CN claimed
CN-104447679-A 2-thiopheneacetonitrile and 2-thiopheneethylamine preparing method INST ADVANCED TECHNOLOGY UNIV SCIENCE & TECHNOLOGY CHINA 2015-03-25 CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250388564-A1 METHODS OF MANUFACTURING PYRIDAZINONE COMPOUNDS MUSK, SMN1; SMN2, PAX3 DRD1 887/4885
US-20200407373-A1 BORONIC ACID DERIVATIVES AND SYNTHESIS THEREOF BTD, BLVRB, BLK DRD1 3180/4885
US-10053426-B2 Process for the synthesis of metyrapone and alkylated metyrapone analogs MET, ABL1, CMPK1 DRD1 38/4885
US-11286270-B2 Boronic acid derivatives and synthesis thereof BTD, BLVRB, BLK DRD1 3180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.